Table 1.
Nuclease | Transfection method | Donor plasmids (ng DNA/106 cells) |
Transfection efficiency (%) | Fold improvement over “no nuclease” control | Proportion double positive | Reference to figure |
---|---|---|---|---|---|---|
CRISPR | Amaxa | 300 | 1.2 | 6.9x | 8.4% | 2C |
CRISPR | Amaxa | 100 | 0.5 | 10x | 3.3% | 2D |
TALEN | Amaxa | 300 | 1.1 | 6.1x | 8.3% | 2E |
TALEN | PEI | 300 | 0.87 | 1.7x | 19% | 2F |
TALEN | Maxcyte | 600 | 5.1 | 51x | 7.4% | - |
TALEN | Maxcyte | 200 | 2.7 | 89x | 3.6% | - |